Mira Pharma Rises On Positive Pre: clinical data for pain drug

Mira Pharmaceuticals

26/08/2024 13:37

** Shares of drug developer MIRA Pharmaceuticals  MIRA.O 
rise 44.3% to $2.67 premarket
    ** Co says low doses of its experimental oral ketamine drug,
ketamir-2, led to a substantial and significant reversal of
nerve pain for 14 and 22 days following the operation
    ** Says at the highest dose, the drug achieved a complete
normalization of the pain threshold, resulting in a 100%
reversal of the neuropathic pain signal
    ** Co was testing the drug in an pre-clinical study, it said
in a regulatory filing
    ** Oral ketamine, under the same experimental conditions,
did not provide significant pain relief, underscoring the
superior efficacy of oral ketamir-2 - MIRA
    ** Up to last close, stock up 76.2% YTD

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))